Skip to main content
SpringerLink
Log in

Radionuklide in der Therapie von Knochenmetastasen

  • Chapter
  • First Online:
Knochenmetastasen

  • 1931 Accesses

Zusammenfassung

Bereits seit den 1940er Jahren werden symptomatische Knochenmetastasen mit osteotropen Radio-Tracern effektiv behandelt. Bei ca. 70% der Patienten kann eine deutliche Schmerzreduktion für längere Zeit erzielt werden. In Kombination mit Bisphosphonaten oder Chemotherapie sowie bei frühzeitigem und wiederholtem Einsatz der Radionuklidtherapie kann eine verbesserte Wirkung erzielt werden. Mit dem Alphaemitter Ra-223-Chlorid konnte auch das Gesamtüberleben verbessert werden. Knochenmetastasen von Schilddrüsenkarzinomen und neuroendokrinen Tumoren lassen sich mit tumorspezifischen Radiopharmaka behandeln. Die direkte Adressierung von Knochenmetastasen beim multiplen Myelom, Prostata-, Mamma- und Lungenkarzinom ist grundsätzlich möglich, muss jedoch noch systematisch evaluiert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Bodei L, Lam M, Chiesa C et al (2008) EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35(10): 1934–1940

    Article  PubMed  Google Scholar 

  • Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ (2005) Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Medicine Commun 26(11): 969–976

    Article  CAS  Google Scholar 

  • Chatterjee M, Chakraborty T, Tassone P (2006) Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur J Cancer 42(11): 1640–1652

    Article  CAS  PubMed  Google Scholar 

  • Couturier O, Faivre-Chauvet A, Filippovich IV et al (1999) Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res 5(10 Suppl): 3165s–3170s

    CAS  PubMed  Google Scholar 

  • Dafermou A, Colamussi P, Giganti M et al (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28(7): 788–798

    Article  CAS  PubMed  Google Scholar 

  • DGN (Deutsche Gesellschaft für Nuklearmedizin) Leitlinien. www.nuklearmedizin.de

  • Durante C, Haddy N, Baudin E et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8): 2892–2899

    Article  CAS  PubMed  Google Scholar 

  • Ezziddin S, Sabet A, Heinemann F et al (2011) Response and long-term control of bone metastases after peptide receptor radionuclide therapy with(177)Lu-octreotate. J Nucl Med 52(8): 1197–1203

    Article  PubMed  Google Scholar 

  • Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6(6): 392–400

    Article  CAS  PubMed  Google Scholar 

  • Gonias S, Goldsby R, Matthay KK et al (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27(25): 4162–4168

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kraeber-Bodere F, Campion L, Rousseau C et al (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27(10): 1487–1493

    Article  CAS  PubMed  Google Scholar 

  • Lam MG, Dahmane A, Stevens WH et al (2008) Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35(4): 756–765

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28(8): 623–630

    Article  CAS  PubMed  Google Scholar 

  • McDevitt MR, Finn RD, Ma D et al (1999) Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med 40(10): 1722–1727

    CAS  PubMed  Google Scholar 

  • Navalkissoor S, Alhashimi DM, Quigley AM et al (2010) Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37(5): 904–912

    Article  PubMed  Google Scholar 

  • Nilsson S, Strang P, Aksnes AK et al (2012) A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48(5): 678–686

    Article  CAS  PubMed  Google Scholar 

  • Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213–223

    Article  CAS  PubMed  Google Scholar 

  • Petrich T, Widjaja A, Musholt TJ et al (2001) Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 28(2): 203–208

    Article  CAS  PubMed  Google Scholar 

  • Ricci S, Boni G, Pastina I et al (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 34(7): 1023–1030

    Article  CAS  PubMed  Google Scholar 

  • Robinson RG, Preston DF, Schiefelbein M, Baxter KG (1995) Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274(5): 420–424

    Article  CAS  PubMed  Google Scholar 

  • Rousseau C, Ferrer L, Supiot S et al (2012) Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 33(3): 679–688

    Article  CAS  PubMed  Google Scholar 

  • Sartor O, Reid RH, Bushnell DL et al (2007) Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109(3): 637–643

    Article  CAS  PubMed  Google Scholar 

  • Schlumberger M, Challeton C, De Vathaire F et al (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37(4): 598–605

    CAS  PubMed  Google Scholar 

  • Schoeneich G, Muller SC, Palmedo H (1998) Indications for nuclear medicine therapy in advanced prostate carcinoma. Urologe A 37(2): 162–166

    Article  CAS  PubMed  Google Scholar 

  • Sciuto R, Festa A, Pasqualoni R et al (2001) Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 66(2): 101–109

    Article  CAS  PubMed  Google Scholar 

  • Sciuto R, Festa A, Rea S et al (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43(1): 79–86

    CAS  PubMed  Google Scholar 

  • Storto G, Klain M, Paone G et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39(1): 35–41

    Article  CAS  PubMed  Google Scholar 

  • Tu SM, Millikan RE, Mengistu B et al (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (9253): 336–341

    Article  CAS  PubMed  Google Scholar 

  • Van Tol KM, Hew JM, Jager PL et al (2000) Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxford) 52(5): 653–659

    Google Scholar 

  • Van Vliet EI, Hermans JJ, de Ridder MA et al (2012) Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions. J Nucl Med 53(9): 1359–1366

    Article  CAS  PubMed  Google Scholar 

  • Van Vliet EI, Teunissen JJ, Kam BL et al (2013) Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 97(1): 74–85

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Jörg Kotzerke & Claudia Brogsitter

Authors
  1. Jörg Kotzerke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Brogsitter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg Kotzerke .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Arnulf Stenzl

  2. Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany

    Tanja Fehm

  3. Medizinische Klinik III, Bereich Endokrinologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany

    Lorenz C. Hofbauer

  4. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Würzburg, Germany

    Franz Jakob

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kotzerke, J., Brogsitter, C. (2014). Radionuklide in der Therapie von Knochenmetastasen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43471-0_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43470-3

  • Online ISBN: 978-3-662-43471-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation